EP0263490A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained-release particulate preparation and process for preparing the same
Assignee: Chugai Pharmaceutical Co Ltd
•
Filing: 1987-10-06
•
Granted: —
•
Expires: 2007-10-06
Abstract
Abstract A sustained-release particulate preparation having a controlled releasing rate of a pharmacologically active agent contained therein in the living body, and a process for preparing the preparation are disclosed. The preparation comprises a polymeric compound which is capable of being degraded in the living body and which is compatible with living tissue, a pharmacologically active agent, and a natural high molecular weight compound of sugar origin or a derivative thereof. The preparation has fine and uniform particle size and can be administered subcutaneously or intramuscularly for obtaining a long-lasting pharmacological activity.
Inventors
- 👤 Minoru Machida
- 👤 Masayuki Arakawa
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 13:27
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/1682; A61K9/1694
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
43 words
A sustained-release particulate preparation which comprises a polymeric compound which is capable of being degraded in the living body and is compatible with living tissue, a pharmacologically active agent, and a natural high molecular weight compound of sugar origin or a derivative thereof.
Claim 2
Dependent Claim
43 words
A sustained-release particulate preparation which comprises a polymeric compound which is capable of being degraded in the living body and is compatible with living tissue, a pharmacologically active agent, and a natural high molecular weight compound of sugar origin or a derivative thereof.
Claim 3
Dependent Claim
24 words
A sustained-release particulate preparation as claimed in Claim 1, wherein said polymeric compound is polylactic acid, polyglycolic acid, polyhydroxybutyric acid or a copolymer thereof.
Claim 4
Dependent Claim
76 words
A sustained-release particulate preparation as claimed in Claim 1, wherein said natural high molecular weight compound of sugar origin or a derivative thereof is selected from the group consisting of chitins and derivatives thereof, chitosans and derivatives thereof, hyaluronic acid and a salt thereof, dextrans having a molecular weight of from about 10,000 to about 150,000, pectins, dextrins having a molecular weight of from about 2,500 to about 150,000, and chondroitin sulfate and a salt thereof.
Claim 5
Dependent Claim
31 words
A sustained-release particulate preparation as claimed in Claim 1, wherein said pharmacologically active agent is an organic compound, a protein or a peptide which is water-insoluble or hardly soluble in water.
Claim 6
Dependent Claim
96 words
A process for preparing a sustained-release particulate preparation which comprises the steps of: (1) dissolving a polymeric compound which is capable of being decomposed in the living body and which is compatible with living tissue in an organic solvent; (2) mixing a pharmacologically active agent with the solution prepared in (1) above; (3) mixing an aqueous solution of a natural high molecular weight compound of sugar origin with the mixture prepared in (2) above, followed by stirring to prepare fine particles containing the pharmacologically active agent; and (4) isolating the thus-produced fine particles from the mixture.
Claim 7
Dependent Claim
96 words
A process for preparing a sustained-release particulate preparation which comprises the steps of: (1) dissolving a polymeric compound which is capable of being decomposed in the living body and which is compatible with living tissue in an organic solvent; (2) mixing a pharmacologically active agent with the solution prepared in (1) above; (3) mixing an aqueous solution of a natural high molecular weight compound of sugar origin with the mixture prepared in (2) above, followed by stirring to prepare fine particles containing the pharmacologically active agent; and (4) isolating the thus-produced fine particles from the mixture.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.